Clinical Report: CKD Markers Linked to Cognitive Risk
Overview
A recent study found that patients with chronic kidney disease (CKD) and elevated urinary protein to creatinine ratio (UPCR) have a significantly higher risk of cognitive impairment. Specifically, a 1-standard deviation increase in UPCR was associated with a 21% greater likelihood of attention and processing speed impairment.
Background
Chronic kidney disease (CKD) is a prevalent condition that often goes unnoticed until advanced stages, yet it is linked to various comorbidities, including cognitive decline. Understanding the relationship between kidney function and cognitive health is crucial for early intervention and management strategies. This study highlights the importance of monitoring CKD markers to assess cognitive risk in affected patients.
Data Highlights
| CKD Marker | Risk of Cognitive Impairment |
|---|---|
| UPCR increase (1-SD) | 21% greater likelihood of impaired attention and processing speed |
| eGFR decrease (1-SD) | 21% increased likelihood of impaired attention and processing speed (attenuated after UPCR adjustment) |
| eGFR <60 mL/min/1.73 m² + UPCR ≥150 mg/g | 38% higher risk of global cognitive impairment |
Key Findings
- Patients with eGFR <60 mL/min/1.73 m² and UPCR ≥150 mg/g had a 38% higher risk of global cognitive impairment.
- A 1-standard deviation increase in UPCR was linked to a 21% greater likelihood of impaired attention and processing speed.
- A 1-standard deviation decrease in eGFR was associated with a 21% increased likelihood of impaired attention and processing speed, but this was attenuated after adjusting for UPCR.
- Joint modeling showed complementary associations between eGFR decline and UPCR regarding cognitive impairment.
- Exclusion of patients with cognitive impairment at baseline was necessary for longitudinal analyses.
Clinical Implications
Healthcare professionals should consider both eGFR and UPCR when assessing cognitive risk in patients with CKD. Early identification of cognitive impairment can lead to timely interventions that may improve patient outcomes. Monitoring these markers can aid in the stratification of patients for cognitive health assessments.
Conclusion
The findings underscore the critical role of CKD severity in predicting cognitive decline, emphasizing the need for integrated management of kidney health and cognitive function.
References
- Huang Z, et al., JAMA Network Open, 2023 -- Chronic Kidney Disease Severity and Risk of Cognitive Impairment
- the ophthalmologist — When the Kidney Meets the Retina
- European Journal of Preventive Cardiology — Prevalence and prognostic importance of chronic kidney disease in patients with coronary heart disease: results from the combined EUROASPIRE IV and V studies
- European Journal of Preventive Cardiology — Cardiovascular–kidney–metabolic syndrome and mortality in a prospective UK cohort study
- Frontiers in Endocrinology — Links Between C-Reactive Protein, Triglyceride-Glucose Index, and Combined C-Reactive Protein-Triglyceride Glucose Index with Progression Patterns in the Cardiovascular-Renal-Diabetes Spectrum
- When the Kidney Meets the Retina
- Prevalence and prognostic importance of chronic kidney disease in patients with coronary heart disease: results from the combined EUROASPIRE IV and V studies
- Cardiovascular–kidney–metabolic syndrome and mortality in a prospective UK cohort study
- KDIGO 2024 CKD Guideline
- Chronic Kidney Disease Severity and Risk of Cognitive Impairment | JAMA Network Open | JAMA Network
- Drivers and mechanisms of cognitive decline in chronic kidney disease | Nature Reviews Nephrology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
